These drugs effectively manage brain metastasis in patients with melanoma and NSCLC and alleviate central nervous system symptoms.310,311 Socazolimab (ZKAB001), a PD-L1-specific monoclonal antibody, has been demonstrated to be safe in nonprogressive localized high-grade osteosarcoma and beneficial for PD-L1-positive and microsatellite instability-high subgroups of patients.312 However, not all anti-PD-1 monoclonal antibodies (mAbs) exhibit therapeutic effects. This evidence concerns the gene CD274 and melanoma.